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C
lonal hematopoiesis (CH) results from the acquisi-
tion of somatic mutations in oncogenic driver genes
in hematopoietic stem and progenitor cells (HSPCs)
leading to the expansion of blood cell clones in
otherwise healthy individuals.1–3CH is rarely found in younger
individuals but its prevalence greatly and continuously
increases beyond 60 years of age when it can be detected at
frequencies of 10% to 20%.4,5 Besides being a pre-malignant
condition for myeloid neoplasms including acute myeloid
leukemia (AML) andmyelodysplastic syndromes (MDS),6,7CH
is also a strong risk factor for thromboembolism8 and
cardiovascular disease.9,10 Mechanistically, it has been shown
that loss-of-function mutations in the epigenetic modifiers
DNMT3A and TET2 lead to de-repression of genes for
inflammatory mediators such as interleukin-1 (IL-1) and
interleukin-6 (IL-6).11,12 Thus, monocytes and macrophages
with mutations in DNMT3A and TET2 acquire a strong pro-
inflammatory phenotype thereby driving development and
rapid progression of atherosclerosis and overt cardiovascular
disease.9,10 A clear pathogenic contribution of CH to other
inflammatory diseases has not yet been formally established but
it is an active area of research.13-15
Infection with the novel severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019
(COVID-19) that is characterized by an interstitial pneumonia of
highly variably clinical extent. While younger individuals that
contract SARS-CoV-2 often remain completely asymptomatic,
severe and fatal cases of COVID-19 are being observed with an
increasing age reaching a fatality rate of up to 60% in patients 80
years and older.16 However, the pathogenesis of severe COVID-
19 has remained enigmatic.17 An excessive release of inflamma-
tory cytokines (ie, cytokine storm) has been observed in severe
COVID-19.18
The striking similarities between CH and severe COVID-19—
both being associated with an advanced age and a pro-
inflammatory state—led us to hypothesize that the presence of
CH might act as a patient-intrinsic, disease-modifying factor for
COVID-19 conferring a higher risk for the development of severe
COVID-19.
We studied a cohort of n=144 individuals ≥50 years with or
without COVID-19 and hospitalized at 3 centers in Switzerland
(University Hospital Zurich n=94, Triemli City Hospital
Zurich n=14, and Cantonal Hospital Winterthur n=36). The
individuals were enrolled in this study after giving informed
consent. The study was approved by the local ethics committee
(KEK-ZHNo. 2020–00892) in accordancewith the declaration
of Helsinki. DNA was extracted from 0.3 ml whole peripheral
blood using the Maxwell® CSC DNA Blood Kit (Promega,
Madison, USA) and was sequenced using the FoundationOne®
Heme assay (Foundation Medicine, Cambridge, USA). NGS
libraries were sequenced using Illumina HiSeqTM 2500 system.
NGS data were analyzed according to the standardized
FoundationOne® Heme assay analysis pipeline. Only muta-
tions with a variant allele frequency (VAF) of 0.01 to 0.4 were
reported if they affected genes recurrently mutated in CH and
myeloid malignancies.1,9 Non-parametric tests were used to
calculate the significance of differences as indicated in the figure
legend and was considered statistically significant if p values
were <0.05. Statistical analysis was calculated using Prism
software.
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We enrolled n=102 patients ≥50 years that required
hospitalization for confirmed COVID-19, and in addition, n=
42 age-, sex-, and comorbidity-matched control patients
hospitalized without COVID-19 in three centers in the Canton
of Zurich, Switzerland, yielding a total cohort of n=144 patients
(Table 1). Patients with COVID-19 were stratified as having
moderate vs severe COVID-19 based on the requirement for
treatment on the intensive care unit (ICU). Furthermore, patients
that died on the regular ward due to COVID-19 were also
classified as having severe COVID-19. The most common reason
for this latter clinical setting was the patient’s wish not to receive
intensive care. The median age of patients with moderate (n=47)
and severe (n=55) COVID-19 was in both cohorts 67 years
(Table 1). Altogether, our cohort was comparable to other
COVID-19 cohorts reported so far.19
In order to determine the prevalence of CH in our cohort of
elderly patients with COVID-19, DNA extracted from whole
blood was subjected to targeted next-generation sequencing
(NGS) using the well-validated FoundationOne® Heme assay
comprising a panel of 406 genes.20 In addition, we sequenced a
well-matched cohort of control patients without COVID-19 to
account for the high variability of CH prevalences reported in the
literature (Table 1).
With a median coverage of 607, we detected 47 mutations
affecting 13 genes in 36/144 (25%) of patients (Supplementary
Table 1, http://links.lww.com/HS/A90). The mutational land-
scape was comparable to previous studies on CH (Fig. 1A), and
as expected, mutations in DNMT3A and TET2 were most
frequently detected accounting for 66% of all mutations.21 There
was no obvious enrichment of particular mutations in patients
with either moderate or severe COVID-19, or in the control
cohort. The remaining mutations affected genes commonly
mutated in CH such as ASXL1, TP53, CBL, and genes for
components of the spliceosome (SF3B1, SRSF2, U2AF1) at,
however, much lower frequencies.1,3 More than one mutation
(up to 3 mutations) per patient were detected in 9/36 (25%)
patients with CH (Fig. 1B). Themedian VAF in the control group,
and in patients with moderate or severe COVID-19 was 0.064,
0.087, and 0.072, respectively, which was not significantly
different (Fig. 1C).
Altogether, at least one mutation was detectable in 11/47
(23.4%) of patients with moderate COVID-19, in 15/55 (27.3%)
of patients with severe COVID-19, and in 10/42 (23.8%) of
patients without COVID-19 (Fig. 1D). Consistent with the well-
established age association of CH, patients with detectable
mutations were older than patients without CH, and this was true
for the control subgroup, and for patients with moderate or
severe COVID-19 (Fig. 1E).
Importantly, the presence of CH was not associated with a
higher likelihood of severe COVID-19 (odds ratio, 1.2; CI 95%,
0.5 to 3.0; p=0.82) (Fig. 1F). Moreover, it has previously been
shown that CH carriers with a VAF of ≥0.1 (corresponding to
≥20% of all blood cells harboring the mutation) had a greater
risk of developing cardiovascular disease driven by inflammatory
cytokines.9 However, clone size did not significantly affect the
risk for severe COVID-19 in our cohort (Fig. 1F).
In summary, we observed a high prevalence of CH in
hospitalized elderly patients with COVID-19. Importantly,
however, there was no significant difference in the
prevalence of CH, its mutational landscape, and clone size
in our cohort of patients with moderate or severe COVID-19,
and in a well-matched control group of patients without
COVID-19. Future studies in larger COVID-19 patient cohorts
might be required to unravel a disease-modifying impact on
Table 1









Age, median years (range) 72 (50–88) 67 (53–89) 67 (50–89) 0.6432
Gender
Male 31 (73.8%) 31 (66%) 45 (81.8%) 0.0738
Female 11 (26.2%) 16 (34%) 10 (18.2%)
Type of comorbidities
Hypertension 17 (40.5%) 25 (53.2%) 26 (47.3%) 0.6914
Diabetes 13 (31%) 13 (27.7%) 22 (40%) 0.2148
Cardiovascular disease 20 (47.6%) 18 (38.3%) 13 (23.6%) 0.1328
Chronic kidney disease 18 (42.9%) 11 (23.4%) 6 (10.9%) 0.1135
Active cancer 6 (14.3%) 4 (8.5%) 7 (12.7%) 0.5407
Rheumatologic / autoimmune disease 3 (7.1%) 5 (10.6%) 4 (7.3%) 0.7291
Pulmonary disease 9 (21.4%) 5 (10.6%) 4 (7.3%) 0.7291
Organ-transplant recipient 2 (4.8%) 1 (2.1%) 2 (3.6%) 0.9999
Number of comorbidities
0 3 6 10 0.5873
1 6 13 18 0.6678
2 20 16 17 0.8326
3 7 7 7 0.7801
4 and more 6 5 3 0.4654
Duration of hospitalization (median days) 9 (1–52) 9 (3–37) 30 (8–64) 0.0001
Mechanical ventilation 0 (0%) 0 (0%) 51 (92.7%) n/a
Mortality 0 (0%) 0 (0%) 13 (23.6%) n/a
∗
The p value refers to the comparison severe vs moderate COVID-19.
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disease severity of a smaller yet potentially clinically relevant
magnitude.
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Figure 1. Clonal hematopoiesis in elderly patients with COVID-19. (A) Mutational landscape of somatic mutations detected in elderly patients with moderate
or severe COVID-19, or in amatched control group of patients without COVID-19. (B) Number of patients with moderate or severe COVID-19 or control patients with
≥1 mutation. (C) Variant allele frequencies (VAFs) in the matched control group, and in patients with moderate or severe COVID-19, respectively. Statistical
significance was calculated using the Mann-Whitney test. (D) Proportion of patients affected by CH in the control group, and in patients with moderate or severe
COVID-19. (E) Age of patients affected by CH in the control group, and in patients with moderate or severe COVID-19. Mann-Whitney test was used to calculate
statistical significance. (F) Odds ratios for the association between CH and the development of severe COVID-19 further stratified according to a variant allele
frequencies (VAF) of <0.1 or ≥0.1 (statistical significance was calculated using Fisher exact test).
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